Free tool
FAERS Monitor: Nuplazid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207318 or its brand name (Nuplazid, Pimavanserin Tartrate). Reports on generic versions are filed under their own applications.
Reports
57,532
Serious
29,715
52% of reports
Hospitalization
9,470
Death reported
14,647
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hallucination13,278
- death11,261
- drug ineffective6,630
- confusional state4,448
- product dose omission issue4,364
- fall4,197
- delusion2,852
- condition aggravated2,605
- hallucination, visual2,413
- parkinson^s disease2,350
- gait disturbance2,289
- urinary tract infection1,923
- somnolence1,793
- adverse drug reaction1,704
- peripheral swelling1,697
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1,269 |
| 2017 | 4,548 |
| 2018 | 4,467 |
| 2019 | 2,606 |
| 2020 | 5,917 |
| 2021 | 4,703 |
| 2022 | 4,300 |
| 2023 | 4,501 |
| 2024 | 7,184 |
| 2025 | 10,493 |
| 2026 | 7,542 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,996,627 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| delusionSignal | 2,852 | 82.0 | 78.8 | 186,417 |
| hallucinationSignal | 13,278 | 78.0 | 76.7 | 834,072 |
| hallucination, visualSignal | 2,413 | 47.0 | 45.1 | 96,355 |
| confusional stateSignal | 4,448 | 10.3 | 10.0 | 36,680 |
| adverse drug reactionSignal | 1,704 | 7.1 | 6.7 | 8,711 |
| product dose omission issueSignal | 4,364 | 5.5 | 5.3 | 16,015 |
| deathSignal | 11,261 | 4.8 | 4.7 | 35,176 |
| fallSignal | 4,197 | 4.7 | 4.5 | 12,086 |
| gait disturbanceSignal | 2,289 | 4.4 | 4.2 | 6,021 |
| urinary tract infectionSignal | 1,923 | 4.2 | 4.0 | 4,593 |
| peripheral swellingSignal | 1,697 | 4.1 | 3.9 | 3,897 |
| somnolenceSignal | 1,793 | 3.3 | 3.1 | 2,834 |
| condition aggravatedSignal | 2,605 | 3.2 | 3.0 | 3,845 |
| drug ineffective | 6,630 | 1.8 | 1.8 | 2,715 |
| parkinson^s disease | 2,350 | 0.0 | 0.0 | 857,375 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.